Toleranzia AB Logo

Toleranzia AB

TOL | ST

Overview

Corporate Details

ISIN(s):
SE0007438577 (+1 more)
LEI:
529900ARVN1D3A4CHI81
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Toleranzia AB is a biotechnology company developing therapies that utilize the immune system to treat rare autoimmune (orphan) diseases. The company's approach focuses on targeting the underlying cause of a disease, aiming to create curative or long-acting treatments that go beyond symptom management. Its lead drug candidate, TOL2, is in development for the treatment of the neuromuscular disease myasthenia gravis (MG). Toleranzia's pipeline also includes TOL3, a candidate for the treatment of the autoimmune blood vessel disease ANCA-vasculitis.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Toleranzia AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Toleranzia AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Toleranzia AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-04 Thomas Eldered Other Sell 12,000,000 5,100,000.00 SEK
2025-04-03 Thomas Eldered Other Sell 23,764,705 10,099,999.62 SEK

Peer Companies

Company Country Ticker View
Medesis Pharma S.A. Logo
Biotech creating CNS and oncology therapies using a proprietary drug delivery platform.
France ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
Biotech R&D firm developing novel drugs, devices, and therapies with a focus on oncology.
Poland MDB
Medigene AG Logo
An immuno-oncology platform creating T cell receptor (TCR)-guided therapies to treat cancer.
Germany MDG1
MedinCell S.A. Logo
Develops and licenses long-acting injectable therapies using proprietary technology.
France MEDCL
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Mendus Logo
Developing immunotherapies using dendritic cells to prevent recurrence of AML & ovarian cancer.
Sweden IMMU
Merck KGaA Logo United States of America 6MK
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Modus Therapeutics Holding AB Logo
Clinical-stage biotech developing sevuparin for sepsis, septic shock, and inflammation.
Sweden MODTX